KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances

Daily Values

Growth Metrics

Merck (MRK) Acquisitions (2016 - 2026)

Merck has reported Acquisitions over the past 15 years, most recently at $8.8 billion for Q1 2026.

Quarterly Acquisitions changed N/A to $8.8 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $18.8 billion through Mar 2026, up 2622.92% year-over-year, with the annual reading at $10.0 billion for FY2025, N/A changed from the prior year.
Acquisitions was $8.8 billion for Q1 2026 at Merck, down from $10.0 billion in the prior quarter.
Over five years, Acquisitions peaked at $10.0 billion in Q4 2025 and troughed at -$1.3 billion in Q4 2024.
The 4-year median for Acquisitions is $598.0 million (2024), against an average of $2.7 billion.
The largest YoY upside for Acquisitions was 12200.0% in 2022 against a maximum downside of 234.44% in 2022.
A 4-year view of Acquisitions shows it stood at -$121.0 million in 2022, then plummeted by 1010.74% to -$1.3 billion in 2024, then soared by 847.17% to $10.0 billion in 2025, then fell by 12.58% to $8.8 billion in 2026.
Per Business Quant, the three most recent readings for MRK's Acquisitions are $8.8 billion (Q1 2026), $10.0 billion (Q4 2025), and -$1.3 billion (Q4 2024).